All In Biotech

NDA 209661 · Duchesnay

Bonjesta

Doxylamine Succinate, Pyridoxine Hydrochloride · Oral

Last checked: Nov 20, 2026Latest source record: Oct 31, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Nov 7, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

18

5 Phase 3, 0 recruiting

FAERS reports

153

71 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 25, 2025.

BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use BONJESTA has not been studied in women with hyperemesis gravidarum. BONJESTA is a fixed dose combination drug product of 20 mg doxylamine succinate, an antihistamine, and 20 mg pyridoxine hydrochloride, a Vitamin B 6 analog, indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. ( 1 )

Mechanism: The mechanism of action of BONJESTA is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 7, 2016 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • BONJESTA · DOXYLAMINE SUCCINATE 20MG; PYRIDOXINE HYDROCHLORIDE 20MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Doxylamine" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • maternal exposure during pregnancy25
  • nausea17
  • drug ineffective16
  • exposure during pregnancy16
  • off label use13
  • abortion spontaneous12
  • product use in unapproved indication10
  • serotonin syndrome10
  • somnolence10
  • vomiting10
  • drug ineffective for unapproved indication9
  • foetal exposure during pregnancy8

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201822
201928
202012
202116
202221
202316
202415
202513
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bonjesta (Doxylamine Succinate/Vit B6)

2024 spending

$47K

Beneficiaries

39

70 claims

Per beneficiary

$1,212

$11.40 per unit

View as table
YearSpending
2020$31,655
2021$45,580
2022$28,004
2023$39,236
2024$47,257

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 47 on PubMed

Sponsor: Duchesnay

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.